# Huanova

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huanova

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.huanova.com
- Latest round: Series A (Oct 9, 2025)
- Investors on record: 7

## About

Based in Shenzhen, China, Huanova is a biotechnology firm focused on developing and producing advanced medical devices, particularly absorbable hemostatic gels designed for various surgical applications.Founded in 2017 in Shenzhen, China, Huanova specializes in high-value medical devices. The company has successfully engaged in 2 deals, with its most recent funding round occurring in October 2025. Huanova was established to address critical needs in the medical field and operates independently without any known subsidiaries or parent companies.Shenzhen Huano Biotechnology Co., Ltd. specializes in the development and production of high-value medical devices, particularly focusing on absorbable hemostatic gels. Their flagship product, the 'self-healing supramolecular' biomaterial, is designed for minimally invasive implantation, with properties that promote healing and regeneration within the body. This innovative technology targets critical needs in neurosurgery, orthopedics, aesthetic medicine, and dentistry, addressing the repair and regeneration of various tissues and organs. The company has successfully received approvals for multiple medical device products, including three new medical device product numbers and several registrations for innovative pharmaceutical excipients. Their products are marketed primarily within China, reflecting a commitment to enhancing local healthcare solutions and reducing reliance on imported medical supplies.Shenzhen Huano Biotechnology Co., Ltd. operates under a business model that facilitates direct transactions with hospitals and healthcare providers, focusing on the sale of their absorbable hemostatic gel and related medical consumables. The company has engaged in significant financing, securing several million in its A+ funding round, which bolsters its capacity to expand production and distribution channels. Their pricing structure is designed to be competitive within the high-value medical device market, enabling partnerships with hospitals that require cost-effective yet innovative solutions for surgical needs. As a B2B entity, Huano’s transactions are characterized by direct sales to healthcare institutions, aiming to address specific clinical challenges with their proprietary technology. The company's strategy positions them favorably in the rapidly growing regenerative medicine materials sector.In October 2025, Huanova raised an undisclosed amount of Series A+ funding led by new investor Shenzhen Guozhong Venture Capital, with participation from new investor Shenzhen Strategic Emerging Industries Investment. The financing will primarily be used to further expand the company's product pipeline based on its independently developed self-healing supramolecular technology platform and to upgrade production capacity for core products. Huanova plans to introduce new products targeting additional therapeutic areas and aims to expand into international markets, with specific focus on regions including Southeast Asia and Europe by the end of 2026.

## Funding rounds

- Series A, Oct 9, 2025 — Shenzhen Guozhong Venture Capital, Lime Capital, Shenzhen strategic emerging industries Investment
- Series A, Jan 10, 2022 — SMECG Talent Equity Investment Fund Management, Zhongxiaodan Venture Capital
- Angel, Sep 1, 2018 — Shenzhen Chuangsai Fund Investment Management, Guoqian Venture Capital

## Investors

- Shenzhen Chuangsai Fund Investment Management — Angel
- Guoqian Venture Capital (https://capitalatlas.ai/funds/guoqian-venture-capital) — Angel
- SMECG Talent Equity Investment Fund Management (https://capitalatlas.ai/funds/smecg-talent-equity-investment-fund-management) — Series A
- Zhongxiaodan Venture Capital (https://capitalatlas.ai/funds/zhongxiaodan-venture-capital) — Series A
- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series A
- Lime Capital (https://capitalatlas.ai/funds/lime-capital) — Series A
- Shenzhen strategic emerging industries Investment — Series A